| Evaluating the Effects of Tasimelteon Vs. Placebo in Delayed Sleep-Wake Phase Disorder (DSWPD) and the CRY1Δ11 Variant NCT06701396 | Fase 3 | Reclutando pacientes |
| Evaluating the Effects of Tasimelteon vs. Placebo in Treating Pediatric Insomnia NCT06953869 | Fase 3 | Reclutando pacientes |
| Evaluating the Effects of Tasimelteon vs. Placebo in Delayed Sleep-Wake Phase Disorder (DSWPD) NCT04652882 | Fase 3 | Completado |
| Trastorno del espectro autista NCT05361707 | Fase 3 | Sin noticias del promotor |
| Safety Study of Tasimelteon for Treatment of Non-24-Hour-Sleep-Wake Disorder in Blind Individuals With No Light Perception NCT01218789 | Fase 3 | Sin noticias del promotor |
| Bioequivalence Study Between Tasimelteon Capsule Formulation and Liquid Suspension Formulation in Healthy Volunteers NCT05572281 | Fase 1 | Completado |
| Evaluating the Effects of Tasimelteon vs Placebo on Sleep Disturbances in SMS NCT02231008 | Fase 2/3 | Completado |
| Evaluation of Next-Day Residual Effects of Tasimelteon Compared With Placebo and Active Control in Healthy Subjects NCT06323655 | Fase 1 | Completado |
| Evaluating the Effects of Tasimelteon vs. Placebo on Jet Lag Type Insomnia NCT03373201 | Fase 3 | Completado |
| Trastorno del espectro autista NCT02776215 | Fase 1 | Completado |
| A Proof of Concept Study to Evaluate the Effects of Tasimelteon and Placebo in Travelers With Jet Lag Disorder NCT03291041 | Fase 2 | Completado |
| Tasimelteon for the Treatment of Non-24-hour Sleep-Wake Disorder (N24HSWD) in Blind Individuals With no Light Perception NCT01429116 | Fase 3 | Completado |
| Open Label Study to Assess the Absolute Bioavailability of Tasimelteon (HETLIOZ™) NCT02130999 | Fase 4 | Completado |
| Trastorno depresivo mayor NCT01428661 | Fase 2/3 | Completado |
| Withdrawal Study to Demonstrate the Maintenance Effect in the Treatment of Non-24-Hour Sleep-Wake Disorder NCT01430754 | Fase 3 | Completado |
| Efficacy and Safety of Tasimelteon Compared With Placebo in Totally Blind Subjects With Non-24-Hour Sleep-Wake Disorder NCT01163032 | Fase 3 | Completado |
| Pharmacokinetics of Tasimelteon Alone and in Combination With a CYP3A4 Inhibitor, Ketoconazole, or a CYP3A4 Inducer, Rifampin. NCT01637636 | Fase 1 | Completado |
| Insuficiencia renal NCT01526746 | Fase 1 | Completado |
| Evaluation of the Pharmacodynamic and Pharmacokinetic Interactions of Tasimelteon and Ethanol NCT01578057 | Fase 1 | Completado |
| Pharmacokinetics of Tasimelteon Alone and in Combination With CYP1A2 Inhibitor, Fluvoxamine NCT01540500 | Fase 1 | Completado |
| Effects of Smoking, Age and Body Size on Pharmacokinetics, Safety and Tolerability on Tasimelteon in Healthy Subjects NCT01477619 | Fase 1 | Completado |
| Insuficiencia hepática NCT01271387 | Fase 1 | Completado |
| A Study to Assess the Effect Tasimelteon on the Cytochrome P450 3A4 and 2C8 Enzymes in Healthy Subjects NCT01402076 | Fase 1 | Completado |